[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"papillomavirus-vaccines\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:papillomavirus-vaccines":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,68,91,124,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100612078","the-effect-of-a-transtheoretical-model-based-educational-intervention-on-first-year-nursing-students-hpv-knowledge-health-beliefs-and-vaccination-behavior-intentions-100612078",false,"NCT07248904","The Effect of a Transtheoretical Model-Based Educational Intervention on First-Year Nursing Students' HPV Knowledge, Health Beliefs, and Vaccination Behavior Intentions","Inclusion Criteria:\n\n* First-year students enrolled in the Nursing Department of the Faculty of Health Sciences\n* Provide written informed consent to participate\n* Agree to attend all educational sessions and data collection appointments during the study period\n* Have sufficient Turkish literacy to read and understand study materials\n* Have not previously received any comprehensive education about HPV infection or HPV vaccination\n\nExclusion Criteria:\n\n* Students who do not agree to participate in the study\n* Students who do not provide written informed consent",true,"ALL","18 Years",{"count":19,"type":20},88,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to examine the impact of a structured educational program based on the Transtheoretical Model (TTM) on HPV knowledge, health beliefs, and vaccination behavioral intentions among first-year nursing students. The study will also evaluate how the intervention affects students' HPV vaccine readiness compared to the TTM.\n\nThe primary questions addressed by the study are:\n\n* Does the TTM-based educational intervention increase students' knowledge about HPV and the HPV vaccine?\n* Does the program change students' health beliefs regarding susceptibility, severity, benefits, and barriers to HPV and the HPV vaccine?\n* Does the program improve students' intentions and readiness to receive the HPV vaccine?\n* Do students move to a higher behavioral readiness stage (from Precontemplation to Contemplation, Preparation, Action, or Maintenance) after the intervention?\n\nThe researcher will compare the TTM-based educational intervention with a control group that did not receive structured education to determine whether a personalized, stage-based approach is more effective in improving HPV-related outcomes among nursing students.\n\nParticipants will:\n\n* Complete baseline questionnaires measuring HPV knowledge, health beliefs, and vaccination intention.\n* The experimental group (intervention group) will receive personalized TTM-based education, face-to-face instruction in modules aligned with the five TTM phases (Precontemplation, Contemplation, Preparation, Action, and Maintenance).\n* The experimental group will participate in educational sessions designed to raise awareness, correct misinformation, support decision-making, and encourage protective behaviors.\n* The control group will not receive any educational program.\n* All participants in the experimental and control groups will complete the same questionnaires again to assess changes after the intervention.\n\nThe TTM-based educational intervention provides:\n\n* Staged counseling\n* Information about HPV and the HPV vaccine\n* Activities to raise awareness, strengthen motivation, and support vaccination adoption\n* Personalized feedback based on student readiness\n* Structured modules focusing on knowledge, belief, and behavior change strategies\n\nThe study population included first-year nursing students enrolled in the Faculty of Health Sciences. A total of 88 participants will be recruited and randomly assigned to either the intervention (n=44) or control (n=44) groups through simple randomization.\n\nThe results of this study are expected to contribute to the development of evidence-based education strategies in nursing, support of behavioral change models in health education, and strengthen the role of future nurses in HPV prevention, vaccine advocacy, and public health practice.",[26,27,28,29,30],"Human Papillomavirus (HPV)","Papillomavirus Vaccines","Health Knowledge, Attitudes, Practice","Students, Nursing","Health Behavior","RECRUITING","2026-03-26",{"date":34,"type":35},"2026-03-27","ACTUAL",{"date":37,"type":35},"2026-01-16",{"date":39,"type":20},"2026-04-30",{"name":41,"class":42},"Cukurova University","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100613458","impact-of-an-e-bug-educational-intervention-on-hpv-vaccine-uptake-in-middle-school-students-100613458","NCT07266857","Impact of an e-Bug Educational Intervention on HPV Vaccine Uptake in Middle School Students","Pilot Observational Comparative Study Evaluating the Impact of the e-Bug Educational Programme on Parental Consent and HPV Vaccination Coverage During the National School-Based Vaccination Campaign in a Middle School in the Alpes-Maritimes","Inclusion Criteria:\n\n* No individual participants are enrolled. The study uses only aggregated, anonymised vaccination data routinely collected by ARS PACA\n\nExclusion Criteria:\n\n* Not applicable. No individual-level inclusion or exclusion criteria are defined, as no participants are enrolled.",{"count":52,"type":20},11000,"OBSERVATIONAL","This study is a non-interventional observational pilot analysis assessing the possible impact of an educational programme (e-Bug) on parental consent and HPV vaccination uptake during the 2023-2024 and 2024-2025 national school-based HPV vaccination campaigns in France. The study focuses on one middle school in the Alpes-Maritimes department where teachers and the school nurse had been previously trained on HPV and used e-Bug educational resources in class as part of routine health education. No research-related intervention was conducted, and the educational programme was not introduced or modified for the purpose of the study. Only aggregated and anonymised vaccination data were used. These data were routinely collected by the Regional Health Agency (ARS PACA) as part of the national vaccination programme and transmitted for analysis. Aggregated data from the pilot school were compared with departmental-level outcomes to describe whether an upstream educational approach may be associated with improved parental acceptance and higher HPV vaccination coverage. This study aims to contribute to the understanding of educational determinants of vaccine uptake in a real-life school setting without involving any participant recruitment or individual data collection.",[56,27,57],"Papillomavirus Infection","Vaccination Coveage","2025-11-25",{"date":60,"type":35},"2025-12-05",{"date":62,"type":35},"2025-05-01",{"date":64,"type":20},"2025-12-31",{"name":66,"class":42},"Centre Hospitalier Universitaire de Nice",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":67},"100557209","remark-addressing-disparities-in-rural-hpv-related-cancer-prevention-100557209","NCT06535139","ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention","ReMARk: A Multi-level Intervention Addressing Disparities in Rural HPV-related Cancer Prevention: Part 3- Evaluation","Inclusion Criteria:\n\n* Adolescents Age 8- to 12-years-old Visited participating clinic in past year or during study No records of receiving both HPV vaccine doses\n* Providers Provide 9- to 12-year-old patients primary care Practice at a participating clinic\n\nExclusion Criteria:\n\n* Adolescents Out of age range\n* Providers Unwilling to consent","8 Years","99 Years",{"count":78,"type":20},4630,[23],"There are three main objectives of the protocol. First, we will evaluate the added clinical- and cost- effectiveness of parent-targeted motivational aids (reminder\u002Frecall and phone-based MI) alone and when combined with community-targeted healthcare access assistance beyond the effects of clinician-targeted training. Second, we will estimate the differential effectiveness of the implementation strategies by patient-level factors (age, race\u002Fethnicity, sex, distance from home to clinic, social vulnerability). Third, we will measure moderation of implementation strategy effectiveness by clinic-level factors (HPV vaccination priority, resources, clinic visit types, scheduling practices, and implementation success).\n\nWithin 11 rural North Central Florida counties, we will evaluate the layering of evidence-based implementation strategies that progressively addressing clinician, parent, and healthcare access barriers faced by rural communities on HPV vaccination rates among 9- to 12-year-olds. To best address our main question of whether layering complementary strategies continues to increase effects on HPV vaccination, we will test our hypotheses with a three-arm cluster randomized study design of nested strategies. The proposed nested study design optimizes evaluation, causal inference, and scientific rigor by putting the maximum number of clinics towards addressing the layering of strategies. Randomization will occur at the clinic level. All clinics will receive implementation strategy A: clinician-targeted recommendation training. A random 20 of 30 of clinics will also receive facilitation of parent-targeted motivational aids (B) for an implementation strategy package of A+B. Finally, a random half of the clinics who receive A+B will also receive community-targeted healthcare access (C) for a total implementation strategy package of A+B+C. This equates to a three-arm cluster randomized trial in which 10 clinics receive clinician- targeted recommendation training alone (A), 10 clinics receive clinician-targeted recommendation training and parent-targeted motivational aids (A+B), and 10 clinics receive clinician-targeted recommendation training, parent-targeted motivational aids, and community-targeted healthcare access (A+B+C).",[27],"2025-09-02",{"date":84,"type":35},"2025-09-09",{"date":86,"type":35},"2024-12-09",{"date":88,"type":20},"2027-07-01",{"name":90,"class":42},"University of Florida",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":104,"conditions":105,"keywords":111,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":67},"100459767","phase-4-immunogenicity-of-gardasil-9-hpv-vaccine-in-people-living-with-hiv-100459767","NCT05266898","Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV","Prospective Observational Immunogenicity Trial of Gardasil-9 HPV Vaccine in People Living With Adequately Managed HIV","AGO-Gard","Inclusion Criteria:\n\n* HIV seropositive\n* immune intact (CD4+ T cell count in peripheral blood \\>200 cells\u002Fml)\n* HIV controlled (peripheral blood HIV viral load \\\u003C1,000 genome copies\u002FmL)\n* Stable on antiretroviral regimen for ≥3 months\n* Gardasil-9 naive and age ≤45 OR\n* documented receipt of 3 doses of Gardasil-4 or Gardasil-9 HPV vaccine\n\nExclusion Criteria:\n\n* Medical contraindication for vaccination (vaccine-naive arm only)\n* Women who are pregnant\n* Acute illness\n* Taking chronic steroids, \\>0.5mg\u002Fkg prednisone or equivalent\n* Taking immune modulating medications\n* Received blood transfusion\u002Fblood products within the past 6 months\n* Recipients of other vaccine products within the past month\n* Inability to provide informed written consent","65 Years",{"count":101,"type":20},250,[103],"PHASE4","The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection.\n\nThe secondary objectives of the study are to observe short term clinical outcomes of prevalent HPV genotype-specific anogenital infections in adults living with HIV who complete the three-dose Gardasil-9 vaccine series, and to determine the protection afforded by Gardasil vaccine over time in previously vaccinated adults living with HIV.\n\nThe clinical hypothesis is that adults with virologically controlled HIV mount a serum antibody response to the nonavalent HPV vaccine that is comparable to HIV negative counterparts. We also postulate that HPV vaccination will provide short-term clinical benefit against HPV infections and disease associated with vaccine genotypes and continuing protection against vaccine genotypes of HPV over time.",[27,106,56,107,108,109,110],"Human Immunodeficiency Virus","Serology","Cervical Intraepithelial Neoplasia","Anal Intraepithelial Neoplasia","Oral Cavity Infection",[112,113,114],"Gardasil-9 HPV vaccine","human papillomavirus","human immunodeficiency virus","2025-04-15",{"date":117,"type":35},"2025-04-18",{"date":119,"type":35},"2022-11-30",{"date":121,"type":20},"2026-06",{"name":123,"class":42},"Louisiana State University Health Sciences Center in New Orleans",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":15,"sex":16,"minAge":132,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":145,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100568625","hpv-vaccine-integrated-service-implementation-research-in-cameroon-100568625","NCT06683664","HPV Vaccine Integrated Service Implementation Research in Cameroon","Human Papillomavirus Vaccine Integrated Service Implementation Research in Cameroon","HPV-PASSREV","Inclusion Criteria:\n\n* Key informant identified by study and implementation teams (purposive sampling by key informant type)\n\nExclusion Criteria:\n\n* Does not provide written informed consent","21 Years",{"count":134,"type":20},40,[23],"The goal of this implementation research study is to understand whether a package of community-based interventions can increase access to and uptake of the human papillomavirus (HPV) vaccine among very young adolescent girls and boys in the North and Far North Regions of Cameroon. The main questions this study aims to answer are:\n\n* Can a package of community-based interventions increase delivery of routine HPV vaccination to boys and girls aged 9-13 in Cameroon's North and Far North Regions?\n* What is the acceptability, feasibility, cost, and potential for maintenance and scale of an integrated health intervention to deliver routine HPV vaccination in Cameroon?\n\nTo evaluate the effectiveness of the intervention, researchers will compare HPV vaccination within regions where the new intervention model is being implemented (intervention areas) to regions where the new routine HPV vaccination delivery model is not being implemented (comparison areas) for approximately 1 year before the new intervention model is implemented and for approximately 9 months after the start of implementation to compare changes over time and between intervention and comparison areas.\n\nThe study will evaluate the effect of the intervention on HPV vaccination delivery using routine health facility data.\n\nTo understand acceptability, feasibility, implementation, and potential for scale, the study will enroll participants including health officials and providers, adolescents girls receiving HPV vaccination and other services in intervention areas, and their parents\u002Fcaregivers. The study will be conducted in two phases, with the first phase focused on gathering formative data through interviews with key informants. This data will be used to inform the design of the intervention, which will be implemented and evaluated in phase 2. Only phase 1 of this study protocol has been currently approved.\n\nIn phase 1, key informant interview participants will be asked to participate in a an interview to discuss HPV vaccination services and their perspectives on how to integrate HPV vaccination within existing community-based and health facility structures and programs. Key informants will include government officials, health program implementers, representatives from non-government organizations working on HPV vaccine delivery, and healthcare providers, as well as community leaders including school and religious leaders.",[27,138,139,140,141,142,143,144],"HPV Vaccinations","HPV Vaccines","HPV Vaccine Acceptability","HPV Vaccine Attitudes","HPV Vaccine Knowledge","Adolescent Health","Adolescent Health Services",[146,147,148,149],"Implementation Science","Cameroon","Implementation Research","Mixed Methods","NOT_YET_RECRUITING","2024-11-08",{"date":153,"type":35},"2024-11-12",{"date":155,"type":20},"2024-11",{"date":157,"type":20},"2025-12",{"name":159,"class":42},"Population Services International",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":15,"sex":16,"minAge":168,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":21,"phases":171,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":180,"leadSponsor":182,"locationsCount":4},"100567371","hpv-vaccine-integrated-service-implementation-research-in-ethiopia-100567371","NCT06667323","HPV Vaccine Integrated Service Implementation Research in Ethiopia","Human Papillomavirus Vaccine Integrated Service Implementation Study in Ethiopia (HPV-VISION)","HPV-VISION","Exclusion Criteria for key informant interviews\n\n\\- Does not provide informed consent\n\nInclusion Criteria for focus group discussions and in-depth interviews:\n\n* Girl: aged 9-14 years, female\n* Caregiver: Parent\u002Flegal guardian of eligible 9-14-year-old girl (above); 18 years of age or older\n\nExclusion Criteria:\n\n* Girl: Does not provide informed assent, including to audio-recording, Parent\u002Flegal guardian does not provide consent\n* Caregiver: Does not provide informed consent, including to audio-recording\n\nInclusion Criteria for exit interviews:\n\n* Girl accompanied by adult (18+) parent\u002Flegal guardian: Aged 9-14 years old; Female; Received a VYA health services supported by the program\\*, including HPV vaccination, on the date of recruitment\n* Girl accompanied by an\u002Fother adult(s) (18+): Aged 9-14 years old; Female; Received a VYA health services supported by the program\\*, including HPV vaccination, on the date of recruitment\n* Girl accompanied by an\u002Fother minor(s) only: Aged 9-14 years old; Female; Received a VYA health services supported by the program\\*, including HPV vaccination, on the date of recruitment\n* Girl completely unaccompanied: Aged 9-14 years old; Female; Received a VYA health services supported by the program\\*, including HPV vaccination, on the date of recruitment\n* Caregiver: Parent\u002Flegal guardian or caregiver of eligible 9-14-year-old girl (above); Accompanying eligible 9-14-year-old girl (above) during care\u002Fservice visit; 18 years of age or older\n\nExclusion Criteria:\n\n* Girl accompanied by adult (18+) parent\u002Flegal guardian: Does not provide informed assent; Parent\u002Flegal guardian does not provide consent; Requires urgent medical treatment or referral\n* Girl accompanied by an\u002Fother adult(s) (18+): • Does not provide informed assent; Caregiver does not provide permission; Requires urgent medical treatment or referral\n* Girl accompanied by an\u002Fother minor(s) only or completely unaccompanied: Does not provide informed assent; Requires urgent medical treatment or referral\n* Caregiver: Does not provide informed consent","9 Years",{"count":170,"type":20},1140,[23],"The goal of this implementation research study is to understand whether a package of community-based interventions can increase access to and uptake of the human papillomavirus (HPV) vaccine among very young adolescent girls in rural Ethiopia. The main questions this study aims to answer are:\n\n* Can a package of community-based interventions increase delivery of routine HPV vaccination to girls aged 9-14 in rural Ethiopia?\n* Is an intervention model that incorporates strategies that address gender norms and gender-specific barriers more effective at increasing delivery of routine HPV vaccination than a model that does not explicitly address gender?\n* What is the acceptability, feasibility, cost, and potential for maintenance and scale of an integrated health intervention to delivery routine HPV vaccination in rural Ethiopia?\n\nTo evaluate the effectiveness of the intervention, researchers will compare HPV vaccination within regions where the new intervention model is being implemented (intervention areas) to regions where the new routine HPV vaccination delivery model is not being implemented (comparison areas) for approximately 1 year before the new intervention model is implemented and for approximately 1 year after the start of implementation to compare changes over time and between intervention and comparison areas.\n\nThe study will evaluate the effect of the intervention on HPV vaccination delivery using routine health facility data.\n\nTo understand acceptability, feasibility, implementation, and potential for scale, the study will enroll participants including health officials and providers, adolescents girls receiving HPV vaccination and other services in intervention areas, and their parents\u002Fcaregivers.\n\nThese participants may be asked to participate in one or more of the following:\n\n* Completing a short questionnaire after receiving health services, including HPV vaccination, and their knowledge and attitudes towards HPV vaccination and experiences of care\n* Participating in an interview or a focus group discussion to discuss HPV vaccination services and the role of the intervention in delivering care",[27,139,140,141,138,142,143,144,174],"Integrated Community-based Intervention Package",[146,148],"2024-10-30",{"date":178,"type":35},"2024-10-31",{"date":178,"type":20},{"date":181,"type":20},"2026-03",{"name":159,"class":42}]